<DOC>
	<DOCNO>NCT01332175</DOCNO>
	<brief_summary>Randomised , placebo-controlled trial continuous positive airway pressure therapy ( CPAP ) versus Provent® Placebo-Provent® define effect Provent® severity obstructive sleep apnea , daytime symptom well measure cardiovascular risk .</brief_summary>
	<brief_title>The Effects Provent® Obstructive Sleep Apnea During Continuous Positive Airway Pressure Therapy Withdrawal</brief_title>
	<detailed_description>Randomised , placebo-controlled trial Provent® versus Placebo-Provent® versus continuous positive airway pressure therapy ( CPAP ) define effect Provent® severity obstructive sleep apnea , daytime symptom well measure cardiovascular risk patient obstructive sleep apnea . Patients successfully treat CPAP randomise one three arm duration 2 week : 1 . Withdraw CPAP use Provent® 2 . Withdraw CPAP use Placebo-Provent® 3 . Continue treatment CPAP</detailed_description>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<criteria>Inclusion criterion : 1 . Objectively confirmed obstructive sleep apnoea ( time original diagnosis ) oxygen desaturation index ( ODI , &gt; 4 % dip ) 10 50/h ESS &gt; 10 ( threshold exclude subject borderline severe form OSA may disproportionate treatment effect ) . 2 . Currently &gt; 10/h oxygen desaturations ( &gt; 4 % dip ) ambulatory nocturnal pulse oximetry perform end 4night period without CPAP . 3 . Treated NCPAP 12 month , minimum compliance 4h per night . 4 . Current ESS &lt; 10 . 5 . Written informed consent . Exclusion criterion : 1 . Previous ventilatory failure ( awake rest arterial oxygen saturation &lt; 93 % arterial PCO2 &gt; 6kPa ) . 2 . Unstable , untreated coronary peripheral artery disease , severe arterial hypertension ( &gt; 180/110mmHg ) . 3 . Previously diagnose CheyneStokes breathe . 4 . Current professional driver . 5 . Any sleep related accident . 6 . Age &lt; 20 &gt; 75 year trial entry . 7 . History chronic nasal obstruction . 8 . Mental physical disability precluding inform consent compliance protocol . 9 . Nonfeasible trial followup ( example , distance followup centre , physical inability ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>